FINWIRES · TerminalLIVE
FINWIRES

$TECH

28 stories mentioning TECHUpdated 30d ago

Every FINWIRES story that references TECH, newest first.

What are analysts saying about TECH?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on TECH?

Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Investors Embrace AI Growth Themes, Reduced Middle East Risks

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.7%, and the actively traded Invesco QQQ Trust (QQQ) advanced 2.1% in Thursday's premarket activity, as investors welcomed signs of stability in the Middle East, while technology shares rallied on expectations for continued AI spending.US stock futures were also higher, with S&P 500 Index futures up 0.7%, Dow Jones Industrial Average futures advancing 0.1%, and Nasdaq futures gaining 2.1% before the start of regular trading.Reports releasing at 8:30 am ET include the personal income and outlays report for May, the third and final estimate report of Q1 gross domestic product, the weekly jobless claims bulletin, the durable goods orders report, and the Chicago Fed national activity index, both for last month.The Kansas City Fed manufacturing index for June posts at 11 am ET.New York Fed President John Williams and Chicago Fed President Austan Goolsbee are slated to speak on Thursday.In premarket action, bitcoin was down by 2.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2.1% higher, Ether ETF (EETH) advanced 3.1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 0.01%.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated by 0.2%, the Vanguard Health Care Index Fund (VHT) was down 0.4%, while the iShares US Healthcare ETF (IYH) was flat, and the iShares Biotechnology ETF (IBB) was up 0.1%.Bio-Techne (TECH) stock rose more than 19% premarket after the company signed a definitive agreement to be acquired by Germany's Merck KGaA for $73 a share, representing an enterprise value of $11.3 billion.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) rose 2.8%, and the iShares US Technology ETF (IYW) was 3.2% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 2.7%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) gained 4.4%, while the iShares Semiconductor ETF (SOXX) rose by 5.1%.Micron Technology (MU) shares were up over 17% in premarket activity after the company overnight reported a fiscal Q3 earnings and revenue beat, and its guidance for the next quarter also came in above market expectations.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.4%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was flat, and the iShares US Consumer Staples ETF (IYK) was marginally lower. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) fell by 0.2%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was flat.Trip.com (TCOM) shares were down more than 11% pre-bell after the company reported lower Q1 non-GAAP earnings.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.4%, while the Vanguard Industrials Index Fund (VIS) gained 1.7% and the iShares US Industrials ETF (IYJ) was flat.MDA Space (MDA) stock was up 2.7% before the opening bell after the company said it would provide digital payload, antennas, and subsystems for Japan's defense communications satellite program under contracts from Mitsubishi Electric.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) fell 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.2%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.1% higher.Barclays (BCS) shares traded up 2% in early hours activity after the company said that the projected capital ratios for its US business remained above the regulatory minimum levels across all nine quarters of the Federal Reserve's stress test.EnergyThe iShares US Energy ETF (IYE) gained 0.03%, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 0.4%.TotalEnergies (TTE) stock was down more than 1% before market open after closing the previous session with a 2% fall. The company said Wednesday it acquired a 10% stake in the Bab Gas Cap Concession in Abu Dhabi, joining an international consortium to develop the major onshore gas field.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 0.7% to $69.84 per barrel on the New York Mercantile Exchange. Natural gas was down by 1.4% to $3.27 per 1 million British Thermal Units. The United States Oil Fund (USO) declined by 0.4%, while the United States Natural Gas Fund (UNG) was 1.3% higher.Gold futures for July were down by 0.2% to $4,000.90 an ounce on the Comex. Silver futures retreated by 1.3% to $57.74 an ounce. SPDR Gold Shares (GLD) declined by 0.2%, and the iShares Silver Trust (SLV) was 0.1% higher.

Dow JonesNasdaq CompositeS&P 500$BCS$BETH$BITO$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$MDA$MU$PMR$QQQ$RTH$SLV$SOXX$SPY$TCOM$TECH$TTE$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Stocks Rise Pre-Bell as Traders Assess Micron Results, Await Key Inflation Data
US Markets

Stocks Rise Pre-Bell as Traders Assess Micron Results, Await Key Inflation Data

US equity markets were pointing higher before the opening bell Thursday as traders parse Micron Technology's (MU) latest financial results and await key inflation and economic data.The S&P 500 rose 0.8%, the Dow Jones Industrial Average edged up 0.1% and the Nasdaq increased 2.2% in premarket activity. The S&P 500 and Nasdaq closed Wednesday trading down for the third consecutive session, while the Dow finished in the green.Shares of Micron jumped 16% pre-bell as the semiconductor manufacturer issued an upbeat fiscal fourth-quarter outlook and reported stronger-than-expected results for the prior three-month period.Micron's "stellar" earnings report eased tech investors' concerns about the artificial intelligence and memory trade, Wedbush Securities said in a Wednesday client note."The tech sector and chip trade still has a lot of room to go higher over the coming months as the stellar demand trends from our recent Asia checks gives us further confidence to own tech stocks into the second half of 2026 with a stronger growth trajectory ahead," according to the brokerage.Qualcomm's (QCOM) stock rose 12% after the company agreed to acquire software infrastructure firm Modular in a roughly $3.92 billion deal. Nvidia (NVDA) gained 1.4%, while Intel (INTC) advanced 5.4%.Bio-Techne (TECH) spiked 22% as the firm agreed to be acquired by Germany's Merck KGaA in a deal worth $11.3 billion.The personal income and outlays report for May is scheduled to be released at 8:30 am ET. The report includes the personal consumption expenditure core price index, the Federal Reserve's preferred inflation metric.Treasury yields rose in premarket action, with the two-year rate advancing 1.3 basis points to 4.15% and the 10-year rate adding 0.8 basis points to 4.41%.Thursday's economic calendar also has the third and final estimate report of the first-quarter gross domestic product at 8:30 am, along with the weekly jobless claims bulletin, the durable goods orders report and the Chicago Fed national activity index, both for last month. The Kansas City Fed manufacturing index for June posts at 11 am.New York Fed President John Williams is slated to speak at 3:40 pm, while Chicago Fed President Austan Goolsbee speaks at 6:30 pm.West Texas Intermediate crude oil declined 1.1% to $69.54 a barrel before the open, while Brent decreased 1.4% to $72.72.Iran's Islamic Revolutionary Guard Corps reportedly said Wednesday it would be "unacceptable and dangerous" for ships to transit new routes through the Strait of Hormuz without coordination with Tehran, CNBC reported, citing local state media.In an emailed report on Wednesday, Stifel said 39 ships moved through the crucial waterway on Monday, still well below the usual average of over 100, but a strong improvement after more than three months of a complete halt in traffic.Darden Restaurants (DRI), TD Synnex (SNX), McCormick (MKC), Acuity (AYI), Commercial Metals (CMC) and BlackBerry (BB) report their latest financial results before the bell, among others.Gold slipped 0.2% to $4,002 per troy ounce, while bitcoin gained 3% to $61,489.

Dow JonesNasdaq CompositeS&P 500$AYI$BB$CMC$DRI$INTC$MKC$MU$NVDA$QCOM$SNX$TECH
Wire

Market Chatter: Bio-Techne Faces Pressure From Ananym Capital to Explore Sale

Bio-Techne (TECH) received a push from activist investor Ananym Capital Management to conduct a strategic review, including a potential sale, Bloomberg reported Monday, citing a letter the media outlet reviewed.In the letter to the board, Ananym argued a sale to a larger industry player would deliver more value than Bio-Techne can achieve as a standalone company, the report said.Ananym has built a stake in the life sciences company, according to the report.Bio-Techne did not immediately respond to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $55.92, Change: $+1.92, Percent Change: +3.55%

$TECH
Research

Piper Sandler Initiates Bio-Techne at Neutral With $65 Price Target

Bio-Techne (TECH) has an average rating of overweight and mean price target of $61.55, according to analysts polled by FactSet.

$TECH
Wire

Bio-Techne's Planned Wilson Wolf Acquisition Underappreciated by Investors, RBC Says

Bio-Techne's (TECH) planned full acquisition of Wilson Wolf is underappreciated by the market, despite its expected boost to Bio-Techne's exposure to cell therapy, RBC Capital Markets said in a note Thursday.Bio-Techne owns 20% of the cell therapy tools company and plans to fully acquire it by the end of 2027. Assuming that Wilson Wolf maintains its double-digit growth and 70% plus earnings before interest, taxes, depreciation and amortization margins, and the deal is viewed as a "jewel" at about 4.4x trailing sales, the analyst said.It adds over 100 basis points to Bio-Techne's structural growth and increases its exposure to the cell therapy market to about 15% of sales, the highest in RBC's coverage, despite mixed early results in cell therapy, with activity and pipelines still strong, the analyst said."And when the market is ready to look out to 2027, we think investors will wake up to the transformative acquisition of Wilson Wolf that is not yet fully appreciated," the analyst added.RBC resumed coverage of Bio-Techne with an outperform rating and a $62 price target.Price: $44.78, Change: $+0.04, Percent Change: +0.09%

$TECH
Insider Trading

Bio-Techne Insider Sold Shares Worth $320,386, According to a Recent SEC Filing

Amy E. Herr, Director, on May 08, 2026, sold 6,636 shares in Bio-Techne (TECH) for $320,386. Following the Form 4 filing with the SEC, Herr has control over a total of 2,880 shares of the company, with 2,680 common shares held directly and 200 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/842023/000091419026000092/xslF345X05/form4.xml

$TECH
Research

Research Alert: CFRA Lowers Rating On Shares Of Bio-techne Corporation To Sell From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target is $44, down from $59, 21.2x our FY 27 EPS estimate. Our multiple is below TECH's one-year historical forward average of 26.1x and the three-year average of 30.7x. We lower our FY 26 EPS estimate by $0.06 to $1.92 and our FY 27 estimate by $0.09 to $2.08. Along with peers, shares have been under pressure due to concerns around NIH and U.S. academic research funding, an important end market for the company, as well as a slowly recovering biotech funding environment. Though we see some indications of improving conditions, we prefer some of TECH's larger, more diversified peers over the near term and think shares are more likely to underperform despite expected sales/EPS growth. We note multiple recent quarters of growth for the large pharma end market and China/APAC sales. Similar to recent commentary from life sciences tools and services peers, TECH sees indications of improving biotech funding, as well as licensing and M&A activity, heading into FY 27.

$TECH
Research

Research Alert: Bio-techne: U.s. Academia Grows Modestly, Q3 Fy 26 Eps Meets Consensus

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Bio-Techne delivered Q3 FY 26 (Jun.) adjusted EPS of $0.53, in-line with consensus, while sales declined 2% to $311.4M amid challenging conditions and unfavorable Commercial Supply timing. Double-digit pharma growth for the sixth consecutive quarter helped offset the gradually recovering biotech funding environment. We believe the company's diversified portfolio and strong financial flexibility position Bio-Techne to capitalize on improving market conditions. Management expressed cautious optimism about improving end-market fundamentals, noting early indicators of better alignment between biotech funding and customer purchasing. U.S. academic markets showed stabilization with low-single-digit growth, representing improvement from recent weakness. Protein Sciences revenue declined 1% to $226.2M with 44.2% operating margin, while Diagnostics and Spatial Biology revenue fell 4% to $85.6M but operating margin improved to 12.1% following the Exosome divestiture.

$TECH

Showing 21-28 of 28

Track with the FINWIRES app suite